Archives
Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
Significant improvement seen in overall survival with pembrolizumab versus placebo and across key subgroups
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
Progression-free survival significantly improved in unresectable hepatocellular carcinoma versus TACE alone
ctDNA-Based Detection of Residual Disease Prognostic for Resected CRC
ctDNA-based detection of molecular residual disease in response to adjuvant chemotherapy prognostic of outcomes
ASA: Deep Learning Model Can Improve Pain Assessment
Model performed with accuracy of 88 percent for Critical Care Pain Observation Tool, 66 percent for visual analog scale
Air Pollution Increases Heart Attacks in Nonsmokers
Findings for same-day nitric oxide levels and average levels for particulate matter in the preceding three days
ASH: Ibrutinib-Venetoclax Beneficial for Relapsed/Refractory Lymphoma
Improvement seen in progression-free survival for patients with relapsed/refractory mantle cell lymphoma
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
ChatGPT Shows Poor Performance in Answering Drug-Related Questions
Nearly three-quarters of drug-related questions received no response or incomplete, wrong answers
ASH: Axi-Cel CAR T-Cell Treatment Effective in High-Risk Lymphoma Patients
Five-year PFS was 28.5 percent and overall survival was 40.3 percent; 40.2 percent of patients did not meet ZUMA-1 eligibility criteria
SABCS: Serum Hormones Can Help ID Benefit of Anastrozole
Women in quartiles 2, 3, and 4 of the estradiol-SHBG ratio demonstrated a relative benefit of anastrozole
